Patents Assigned to University of Genoa
-
Publication number: 20200368096Abstract: A comprehensive system for treatment of wrist joint proprioception. The system includes a manipulandum unit and a controller. The unit includes a base, a handle, a linkage assembly, and motors. The base supports a subject's forearm, and the handle is gripped by the palm. The linkage assembly connects the handle to the base, and establishes three DOFs. The motors are operatively connected to the linkage assembly. The controller is programmed to actuate, and receive feedback information from, each of the plurality of motors. Further, the controller is programmed to perform wrist proprioception assessment operations by actuating the plurality of motors to effectuate movement of the handle relative to the base in a prescribed manner indicative of position motion sense acuity as an objective measure of wrist proprioception functioning. The controller is optionally further programmed to perform rehabilitation training via controlled operation of the unit and a virtually reality environment.Type: ApplicationFiled: August 14, 2020Publication date: November 26, 2020Applicants: Regents of the University of Minnesota, Nanyang Technological University, Fondazione Istituto Italiano di Tecnologia (Italian Institute of Technology), Università degli Studi di Genova (University of Genoa)Inventors: Lorenzo Masia, Juergen Konczak, Giulio Sandini, Leonardo Cappello
-
Patent number: 10786415Abstract: A comprehensive system for treatment of wrist joint proprioception. The system includes a manipulandum unit and a controller. The unit includes a base, a handle, a linkage assembly, and motors. The base supports a subject's forearm, and the handle is gripped by the palm. The linkage assembly connects the handle to the base, and establishes three DOFs. The motors are operatively connected to the linkage assembly. The controller is programmed to actuate, and receive feedback information from, each of the plurality of motors. Further, the controller is programmed to perform wrist proprioception assessment operations by actuating the plurality of motors to effectuate movement of the handle relative to the base in a prescribed manner indicative of position motion sense acuity as an objective measure of wrist proprioception functioning. The controller is optionally further programmed to perform rehabilitation training via controlled operation of the unit and a virtually reality environment.Type: GrantFiled: March 17, 2016Date of Patent: September 29, 2020Assignees: Regents of the University of Minnesota, Nanyang Technological University, Italian Institute of Technology, University of GenoaInventors: Lorenzo Masia, Juergen Konczak, Giulio Sandini, Leonardo Cappello
-
Patent number: 8981065Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: July 8, 2013Date of Patent: March 17, 2015Assignees: Novo Nordisk A/S—Novo Alle, Innate Pharma S.A.S., University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Patent number: 8637258Abstract: The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.Type: GrantFiled: June 10, 2010Date of Patent: January 28, 2014Assignees: Novo Nordisk A/S, University of Genoa, Innate Pharma, S.A.Inventors: Soren Berg Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Andreas Nicolai Reumert Wagtmann
-
Patent number: 8119775Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: October 2, 2008Date of Patent: February 21, 2012Assignees: University of Genoa, Innate Pharma S.A.S., Novo Nordisk A/SInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Publication number: 20090081240Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: October 2, 2008Publication date: March 26, 2009Applicants: Novo Nordisk A/S, Innate Pharma, University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 6080731Abstract: 5',5'-Pyrophosphates of non-naturally occurring nucleosides selected from thymine-3'-azido-2',3'-dideoxy-D-riboside, 5-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthing-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutical pharmaceutical compositions or as pro-drugs encapsulated into biological carriers, e.g., transformed erythrocytes, for targeting to specific cell population responsible of the development of the pathological disorders.Type: GrantFiled: July 1, 1998Date of Patent: June 27, 2000Assignees: Biosearch Italia, S.p.A., University of GenoaInventors: Antonio De Flora, Umberto Benatti, Marco Giovine